23andMe seeks new bids after $305 million offer from its co-founder

23andMe is seeking court approval to reopen bidding for its assets, including customer genetic data, after receiving a $305 million offer from co-founder Anne Wojcicki's TTAM Research Institute, exceeding Regeneron's prior $256 million lead bid. Regeneron, while still interested, is requesting a $10 million breakup fee if Wojcicki's bid prevails, arguing that the initial auction's rules should be upheld; the bankruptcy follows declining demand and a significant 2023 data breach, raising concerns among lawmakers about the potential sale of sensitive customer data.

Analysis

The bankrupt genetic testing firm 23andMe is petitioning the U.S. Bankruptcy Court to reopen bidding for its assets, including extensive customer genetic data, after receiving a $305 million offer from TTAM Research Institute, a nonprofit established by 23andMe's co-founder Anne Wojcicki. This new offer substantially surpasses the $256 million bid from Regeneron Pharmaceuticals (REGN), which was previously selected as the lead offer following a May bankruptcy auction. 23andMe's Chapter 11 filing in March was precipitated by declining consumer interest and a significant 2023 data breach that compromised millions of customer records, raising concerns among U.S. lawmakers over the potential sale of sensitive genetic information from its database of over 15 million DNA profiles. Regeneron is contesting the bid reopening, arguing the prior auction was definitive, and seeks a $10 million breakup fee should Wojcicki's higher offer be accepted, underscoring the contentious nature of the asset sale. The significantly increased offer from TTAM, which was initially valued as a $146 million backup bid, highlights the considerable underlying value attributed to 23andMe's genetic database despite the company's financial distress and data security issues.

Key Decisions for Investors

• Investors in Regeneron (REGN) should monitor the resolution of the 23andMe asset bidding, as securing the genetic data offers strategic potential, while a higher acquisition cost or losing the bid would necessitate a re-evaluation of this specific growth avenue.
• The substantial increase in valuation for 23andMe's genetic assets, despite its bankruptcy and prior data breach, signals strong market interest in large-scale genomic databases, potentially impacting valuations and M&A strategies across the biotech and health-tech sectors.
• The ongoing legal proceedings and lawmaker scrutiny concerning 23andMe's customer data sale emphasize the critical importance of robust data governance, cybersecurity, and ethical considerations for companies handling sensitive personal information, which are increasingly material risk factors.
• The competitive bidding led by a co-founder's nonprofit (TTAM Research Institute) for sensitive data assets could establish a precedent for how such assets are handled in future bankruptcies, particularly concerning data stewardship and potential research-focused acquisitions.